Ryoncil Q4 Net Revenue of US$36M and US$115M for Full Year
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Mesoblast Limited has announced its financial results for the fourth quarter and full year, reporting significant net revenue from Ryoncil®. The Chief Executive expressed satisfaction with the revenue growth and anticipated continued momentum in the upcoming fiscal year. Ryoncil® is the first FDA-approved mesenchymal stromal cell therapy for pediatric patients with steroid-refractory acute graft-versus-host disease.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Mesoblast
- Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility
- Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
- Patient Recruitment Target Achieved in CLBP Pivotal Trial
- Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
- Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products
Later from Mesoblast
- Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
- Pivotal Phase 3 Trial in CLBP Achieves 300 Treated Patients
- Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
- Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
- Major Milestone Treatment Completed in P3 Trial for CLBP
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast